Coherus BioSciences insists it is “prepared for any competition if anybody else comes” following Amneal’s recent announcement that it has in-licensed two additional pegfilgrastim biosimilar pipeline programs: an on-body injector and a pre-filled autoinjector.
The California-based firm is currently the sole player offering biosimilars in the US to Amgen’s complete range of Neulasta (pegfilgrastim) products, including a novel autoinjector version of its existing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?